期刊
WILEY INTERDISCIPLINARY REVIEWS-RNA
卷 14, 期 3, 页码 -出版社
WILEY
DOI: 10.1002/wrna.1760
关键词
bladder cancer; circRNA; splicing; urothelial carcinoma
类别
Bladder cancer is the most common malignancy of the urinary tract worldwide. The disease can be treated with surgery, chemotherapy, and immunotherapy, but many patients develop resistance to these treatments and experience aggressive metastasis with poor prognosis. The molecular heterogeneity of bladder cancer is a significant limitation, but the dysregulation of RNA splicing has been identified as a potential target for diagnosis, prognosis, and therapy. Targeting specific splicing factors, mRNA splicing variants, and circular RNAs has shown promising antitumor effects, offering new possibilities for improving the management of this devastating cancer type.
Bladder cancer is the most common malignancy of the urinary tract worldwide. The therapeutic options to tackle this disease comprise surgery, intravesical or systemic chemotherapy, and immunotherapy. Unfortunately, a wide number of patients ultimately become resistant to these treatments and develop aggressive metastatic disease, presenting a poor prognosis. Therefore, the identification of novel therapeutic approaches to tackle this devastating pathology is urgently needed. However, a significant limitation is that the progression and drug response of bladder cancer is strongly associated with its intrinsic molecular heterogeneity. In this sense, RNA splicing is recently gaining importance as a critical hallmark of cancer since can have a significant clinical value. In fact, a profound dysregulation of the splicing process has been reported in bladder cancer, especially in the expression of certain key splicing variants and circular RNAs with a potential clinical value as diagnostic/prognostic biomarkers or therapeutic targets in this pathology. Indeed, some authors have already evidenced a profound antitumor effect by targeting some splicing factors (e.g., PTBP1), mRNA splicing variants (e.g., PKM2, HYAL4-v1), and circular RNAs (e.g., circITCH, circMYLK), which illustrates new possibilities to significantly improve the management of this pathology. This review represents the first detailed overview of the splicing process and its alterations in bladder cancer, and highlights opportunities for the development of novel diagnostic/prognostic biomarkers and their clinical potential for the treatment of this devastating cancer type. This article is categorized under: RNA Processing > Splicing Regulation/Alternative Splicing RNA in Disease and Development > RNA in Disease
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据